![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: WDR31 |
Gene summary for WDR31 |
![]() |
Gene information | Species | Human | Gene symbol | WDR31 | Gene ID | 114987 |
Gene name | WD repeat domain 31 | |
Gene Alias | WDR31 | |
Cytomap | 9q32 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q8NC90 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
114987 | WDR31 | HCC1 | Human | Liver | HCC | 3.24e-20 | 2.09e+00 | 0.5336 |
114987 | WDR31 | HCC2 | Human | Liver | HCC | 1.32e-25 | 2.81e+00 | 0.5341 |
114987 | WDR31 | HCC5 | Human | Liver | HCC | 8.42e-28 | 2.06e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | ![]() |
Breast | IDC | ![]() |
Breast | DCIS | ![]() |
Cervix | CC | ![]() |
Cervix | HSIL_HPV | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WDR31 | SNV | Missense_Mutation | novel | c.152N>A | p.Thr51Asn | p.T51N | Q8NA23 | protein_coding | tolerated(0.13) | benign(0.037) | TCGA-AC-A3BB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
WDR31 | SNV | Missense_Mutation | novel | c.354N>A | p.Phe118Leu | p.F118L | Q8NA23 | protein_coding | tolerated(0.54) | benign(0.047) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WDR31 | SNV | Missense_Mutation | c.596N>C | p.Arg199Thr | p.R199T | Q8NA23 | protein_coding | tolerated(0.28) | benign(0.061) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
WDR31 | SNV | Missense_Mutation | rs549756901 | c.1006N>A | p.Ala336Thr | p.A336T | Q8NA23 | protein_coding | tolerated(0.82) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
WDR31 | SNV | Missense_Mutation | c.667N>C | p.Ala223Pro | p.A223P | Q8NA23 | protein_coding | deleterious(0.02) | probably_damaging(0.963) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR | |
WDR31 | SNV | Missense_Mutation | novel | c.143G>A | p.Arg48Lys | p.R48K | Q8NA23 | protein_coding | tolerated(0.95) | benign(0) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
WDR31 | SNV | Missense_Mutation | novel | c.136N>C | p.Glu46Gln | p.E46Q | Q8NA23 | protein_coding | tolerated(0.06) | benign(0.31) | TCGA-VS-A8Q8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
WDR31 | SNV | Missense_Mutation | c.642N>C | p.Leu214Phe | p.L214F | Q8NA23 | protein_coding | deleterious(0.01) | possibly_damaging(0.773) | TCGA-AA-3851-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
WDR31 | SNV | Missense_Mutation | c.485G>A | p.Cys162Tyr | p.C162Y | Q8NA23 | protein_coding | deleterious(0) | benign(0.066) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
WDR31 | SNV | Missense_Mutation | rs771901789 | c.50C>T | p.Ser17Leu | p.S17L | Q8NA23 | protein_coding | tolerated_low_confidence(0.73) | benign(0) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |